RANBAXY

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated February 26, 2010, titled "Daiichi Sankyo Group to Expand its Business Scope in Japan through Establishment of Daiichi Sankyo Espha Co., Ltd". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_pr_26022010.ZIP target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange vide notes to Accounts in the Audited Financial Results for the year ended December 31, 2009 (taken on record by the Board of Directors of the Company at its meeting held on February 25, 2010) that: "With references to qualification of the previous statutory auditors as mentioned in their report on the accounts of the Company for the year ended December 31, 2008, Central Government vide its letter dated May 12, 2009 and February 03, 2010 approved the waiver of recovery of excess remuneration paid to the Executive Directors of the Company".

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated February 25, 2010, titled "Ranbaxy Repeats Strong Operating Performance - FY 2009 Profit Before Tax Over Rs. 1000 Crores; Global Sales at Rs. 7344 Crores". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_pr_25022010.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding the consolidated Results for the year ended on 31-DEC-2009 as follows: Net Sales of Rs. 732940.3 lacs for year ending on 31-DEC-2009 against Rs. 724140.7 lacs for the year ending on 31-DEC-2008. Net Profit / (Loss) of Rs. 29649.2 lacs for the year ending on 31-DEC-2009 against Rs. (95120.5) lacs for the year ending on 31-DEC-2008.

Ranbaxy Laboratories Ltd has informed the Exchange regarding the standalone Results for the year ended on 31-DEC-2009 as follows: Net Sales of Rs. 452118 lacs for year ending on 31-DEC-2009 against Rs. 430836.2 lacs for the year ending on 31-DEC-2008. Net Profit / (Loss) of Rs. 57198.4 lacs for the year ending on 31-DEC-2009 against Rs. (104480.2) lacs for the year ending on 31-DEC-2008.

Ranbaxy Laboratories Ltd has informed the Exchange regarding the standalone Results for the quarter ended on 31-DEC-2009 as follows: Net Sales of Rs. 152288.1 lacs for quarter ending on 31-DEC-2009 against Rs. 95460.5 lacs for the quarter ending on 31-DEC-2008. Net Profit / (Loss) of Rs. 48823.3 lacs for the quarter ending on 31-DEC-2009 against Rs. (80655.4) lacs for the quarter ending on 31-DEC-2008.

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated February 10, 2010, titled " Daiichi Sankyo to Launch Innovator Products in Mexico through Ranbaxy, Companies to Fully Leverage the Synergistic Power of the Hybrid Business Model ". A copy of the press release shall be available on the NSE website http://www.nseindia.com) under: Corporates > Latest announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_pr_10022010.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated January 19, 2010, titled "Ranbaxy Enters Vaccines Arena With The Acquisition Of Product Rights And Manufacturing Facility From Biovel". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_19012010.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange that the Company has decided to submit and publish the Audited Financial Results for the financial year ended December 31, 2009 on or before March 31, 2010 instead of Unaudited Results of the last quarter ended December 31, 2009.

Ranbaxy Laboratories Ltd has informed the Exchange that the ESOPs Allotment Committee of Directors vide Resolution by Circulation Passed on January 13, 2010, allotted 105,888 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 420,523,246 Equity Shares of Rs. 5/-each aggregating Rs.2,102,616,230/-

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated January 04, 2010, titled " Ranbaxy Launches a New Chemical Entity (NCE), Lulifin (Luliconazole) in India- The Dermatological Product in-licensed from Summit Pharmaceuticals, Japan, strengthens Ranbaxy's skin portfolio."A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_pr_04012010.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated December 29, 2009, titled "Ranbaxy to transfer stake in Ranbaxy (Guangzhou China) Limited to HNG Chembio Pharmacy Co. Ltd. " A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_pressrelease_29122009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a Statement dated December 24, 2009, which is being issued by Ohm Laboratories Inc., New Jersey, USA, a wholly owned subsidiary of the Company. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_st_24122009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated December 21, 2009, titled "Daiichi Sankyo to Leverage Ranbaxy's Presence in Africa for Marketing and Distribution Olmesartan to be launched in six African countries." A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_pr_21122009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated December 08, 2009, titled "Ranbaxy and Nippon Chemiphar dissolve their Joint Venture 'Nihon Pharmaceutical Industry Co. Ltd' in Japan". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_pr_08122009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated November 12, 2009, titled "Ranbaxy gains WHO pre-qualification for Indinavir - 400 mg ARV capsules". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_12112009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange that the auditors have conducted the limited review for the un-audited financial results for the quarter ended September 30,2009 and the year to date results for the period January 1, 2009 to September 30, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/RANBAXY_LR_03112009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange vide notes to Accounts in the Unaudited Financial Results for the quarter and nine months year ended September 30, 2009 (taken on record by the Board of Directors of the Company at its meeting held on October 26, 2009) that: "With the references to qualification of the previous statutory auditors as mentioned in their report on the accounts of the Company for the year ended December 31, 2008, Central Government vide letter dated May 12, 2009, approved the waiver of recovery of excess remuneration paid to the working Directors of the Company.

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated October 26, 2009, titled "Ranbaxy Records Consistent Improvement in Operating Performance". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/RANBAXY_PR_26102009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding the standalone Results for the quarter ended on 30-SEP-2009 as follows: Net Sales of Rs. 118960.4 lacs for quarter ending on 30-SEP-2009 against Rs. 114629.5 lacs for the quarter ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 18608.1 lacs for the quarter ending on 30-SEP-2009 against Rs. (35293) lacs for the quarter ending on 30-SEP-2008.

Ranbaxy Laboratories Ltd has informed the Exchange that the ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on October 12, 2009, allotted 45,445 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 420417358 Equity Shares of Rs.5 each aggregating Rs. 2,102,086,790/-.

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated October 05, 2009, titled "Daiichi Sankyo to Leverage Ranbaxy's Presence in Mexico for Marketing and Distribution; New Division will bring Daiichi Sankyo's innovator products to Mexican market". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_05102009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has submitted to the Exchange a copy of the Result of Postal Ballot. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_rpb_22092009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated September 17, 2009, titled "Ranbaxy in-licenses cosmetic product, Neuronox, from Medy - Tox, South Korea, for Indian market - Strengthens presence in Dermatological segment". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_17092009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated September 03, 2009, titled "Ranbaxy Launches Authorized Generic Version of Rocaltrol". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/RANBAXY_PR_03092009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange that the auditors have conducted the limited review for the un-audited financial results for the quarter ended June 30,2009 and year to date results from the period January 1, 2009 to June 30, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/RANBAXY_LR_01092009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated September 01, 2009, titled "Daiichi Sankyo and Ranbaxy Leverage New Business Model with Launch of EVISTA in Romania". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/RANBAXY_Pr_01092009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated August 24, 2009, titled "Ranbaxy receives Final Approval from USFDA to manufacture and market Glycopyrrolate Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_24082009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated August 12, 2009, titled "Ranbaxy Launches Protein Supplement - 'Revitalite' in India; Strengthens Presence in Nutritional Supplements Market". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_12082009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated August 11, 2009, titled "Ranbaxy Receives Final Approval From USFDA To Market Sumatriptan Succinate Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/RANBAXY_PR_11082009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has submitted to the Exchange a copy of the notice pursuant to section 192A of the Companies Act, 1956 read with the Companies ( passing of the resolution by Postal Ballot ) Rules, 2001. A copy of the notice of the postal ballot shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_PB_10082009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated August 04, 2009, titled "Ranbaxy Launches Generic Losartan in Malaysia on Day-One ". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/RANBAXY_PR_04082009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated July 29, 2009, titled "Ranbaxy gains approval to market Ran-Ropinirole Tablets in Canada". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_29072009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange vide notes to Accounts in the Unaudited Financial Results (Provisional) for the quarter ended June 30, 2009 (taken on record by the Board of Directors of the Company at its meeting held on July 24, 2009) that: "With reference to qualification of the Auditors as mentioned in their reports on the accounts of the Company for the year ended December 31, 2008, Central Government vide letter dated May 12, 2009, approved the waiver of recovery of excess remuneration paid to the Working Directors of the Company. Requisite approvals for appointment for

Ranbaxy Laboratories Ltd has informed the Exchange that the Board of Directors at its meeting held on July 24, 2009, the Board has approved for seeking consent of the Shareholders through postal ballot for appointment and payment of remuneration to - (I) Mr. Atul Sobti as CEO & Managing Director of the Company for a period of three years effective May 24, 2009 and (II) Mr. Malvinder Mohan Singh as Chairman, CEO & Managing Director for the period from December 19,2008 to May 24, 2009 ( the date he stepped down from the said positions).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated July 24, 2009, titled "Q2 FY 2009 Results; Profit After Tax Rs.6,931 MN, Global Sales At Rs.17,953 MN 14% Growth Over Previous Quarter". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/RANBAXY_pr_24072009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding the standalone Results for the half year ended on 30-JUN-2009 as follows: Net Sales of Rs. 180869.4 lacs for half year ending on 30-JUN-2009 against Rs. 220420.7 lacs for the half year ending on 30-JUN-2008. Net Profit / (Loss) of Rs. (10232.8) lacs for the half year ending on 30-JUN-2009 against Rs. 12715 lacs for the half year ending on 30-JUN-2008.

Ranbaxy Laboratories Ltd has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2009 as follows: Net Sales of Rs. 100647.3 lacs for quarter ending on 30-JUN-2009 against Rs. 121692.1 lacs for the quarter ending on 30-JUN-2008. Net Profit / (Loss) of Rs. 67545 lacs for the quarter ending on 30-JUN-2009 against Rs. 2372.8 lacs for the quarter ending on 30-JUN-2008.

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated July 23, 2009, titled "Ranbaxy's non-sterile drug plant at Dewas receives GMP Compliance approval from MHLW- Japan - Approval applies to all product filings for Japan for a period of 5 years". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/RANBAXY_pr_23072009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated July 21, 2009, titled "Ranbaxy receives Final Approval to manufacture and market RAN-SIMVASTATIN tablets in Canada". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_pr_21072009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated July 20, 2009, titled "Ranbaxy receives Final Approval to manufacture and market RAN-AMLODIPINE tablets in Canada". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_20072009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange that "The ESOPs Allotment Committee of Directors vide Resolution by Circulation passed on July 13, 2009, allotted 2,160 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 420371913 Equity Shares of Rs. 5 each aggregating Rs.2101859565/-"

Ranbaxy Laboratories Ltd has informed the Exchange that the auditor's have conducted the limited review of the unaudited financial results (Provisional) for the three months ended March 31, 2009. A copy of the Limited Review report shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_LR_29052009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange that the members of the company at the Annual General Meeting (AGM) held on May 29, 2009 have approved : 1) Adoption of audited Profit & Loss Account for the year ended December 31, 2008 and the Balance Sheet as at that date and the Reports of the Directors and the Auditors thereon. 2) Appointment of M/s BSR & Co. as Auditors of the Company to hold office upto the conclusion of the next AGM and authorized the Board of Directors or Committee thereof to fix the remuneration.3) Appointment of Mr. Takashi Shoda as a Director of the Company who wa

Ranbaxy Laboratories Ltd has informed the Exchange that in the Board meeting of the Company held on May 24, 2009: a) Mr. Malvinder Mohan Singh stepped down as Chairman, CEO & Managing Director of the Company with immediate effect; and b) Mr. Sunil Godhwani, Mr. Balinder Singh Dhillon and Mr. Atul Sobti resigned from the Directorship of the Company with immediate effect. At the subsequent Board meeting held on May 24, 2009: a) Dr. Tsutomu Une, Non-Executive Director was elected as the Chairman of the Board of Directors of the Company; and b) Mr. Atul Sobti was appointed as CEO & Managing Direct

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated May 24, 2009, titled "Ranbaxy and Daiichi Sankyo Announce Reconstitution of Ranbaxy Executive Leadership." A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_25052009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated May 21, 2009, titled "Ranbaxy consolidates presence in Dermatology Segment - Acquires Brands from Ochoa Laboratories Ltd.". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_pr_21052009.ZIP target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated May 06, 2009, titled "Basics, Ranbaxy's subsidiary in Germany, to provide generic medicines in Germany under AOK agreement". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/RANBAXY_PR_06052009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated May 04, 2009, titled "RANBAXY COMMENCES PHASE-III CLINICAL TRIALS FOR ITS NEW ANTI-MALARIAL MOLECULE". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy01_PR_04052009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated May 02, 2009, titled "Ranbaxy Voluntarily Recalls Nitrofurantoin Capsules in the U.S.". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_04052009.zip target=NEW> For more details click here.</a>